DEVELOPMENT AND IN VITRO EVALUATION OF TOPICAL FORMULATION WITH CANNABIDIOL AND MUPIROCIN FOR THE CONTROL OF INFECTIONS AND Staphylococcus aureus BIOFILMS IN ORTHOPEDIC IMPLANTS
Staphylococcus aureus, biofilm, cannabidiol, mupirocin, orthopedic implants.
Surgical site infections (SSIs) associated with orthopedic implants remain a significant clinical challenge, particularly due to the formation of bacterial biofilms that exhibit high resistance to conventional therapies. This doctoral thesis proposes the development and in vitro evaluation of a topical formulation combining cannabidiol (CBD) and mupirocin, using anhydrous lanolin as the pharmaceutical base, aimed at controlling Staphylococcus aureus strains, including methicillin-resistant variants (MRSA), commonly implicated in implant-related infections.
The research involved the formulation design, physicochemical characterization, and assessment of antimicrobial and antibiofilm activity. Methods such as minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), Checkerboard Assay, and Time-Kill Curves confirmed a synergistic effect between CBD and mupirocin. Specific assays were also performed to quantify both biofilm formation inhibition and the reduction of mature biofilm viability.
The results confirmed the formulation’s effectiveness in inhibiting resistant S. aureus strains and disrupting established biofilms, highlighting its therapeutic potential in orthopedic applications. The study further emphasizes CBD as an innovative adjunctive agent with antimicrobial, antibiofilm, and anti-inflammatory properties, offering promising directions for the development of effective and safe topical treatments.